Recursion Pharmaceuticals is trading at $4.16, up 5.32%, in live trading on October 9, 2026, with broader biotech strength offering the clearest context for the gain.
- The XBI is up 2.50%; sector sentiment has been buoyed by successful biotech IPOs and M&A activity. This supports a sector-driven explanation, not a company-specific catalyst.
- Recent coverage reports ARK bought about 1.9 million shares on October 7; that earlier purchase is not confirmed as the direct cause of today’s move.